Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

70.64
-0.0392-0.06%
Post-market: 70.10-0.5400-0.76%18:24 EDT
Volume:465.49K
Turnover:32.86M
Market Cap:3.67B
PE:6.36
High:70.80
Open:70.61
Low:70.07
Close:70.68
52wk High:74.59
52wk Low:56.44
Shares:51.90M
Float Shares:51.90M
Volume Ratio:0.80
T/O Rate:0.90%
Dividend:0.80
Dividend Rate:1.13%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.31
PE(LYR):23.09

Loading ...

Exchange-Traded Funds Mixed as US Equities Fall After Midday

MT Newswires Live
·
Yesterday

Eli Lilly and Co Stock (LLY) Moved Up by 3.01% on Sep 14: Drivers Behind the Movement

TradingKey
·
Yesterday

UnitedHealth Earnings Growth Outlook Unlikely to Change, UBS Says

MT Newswires Live
·
Sep 14

Dow Jones Top Company Headlines at 11 am ET: Microsoft Sets Limits for AI Models as Altman Details Control Risks | Dell's ...

Dow Jones
·
Sep 14

Eli Lilly Announces R$ 0.2 Per Unit Dividend for 3Q 2026 BDRs

Reuters
·
Sep 14

Biofrontera announces FDA approval of Ameluz supplemental new drug application

TIPRANKS
·
Sep 14

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid AI Pullback

MT Newswires Live
·
Sep 14

Sector Update: Healthcare Stocks Rise Premarket Monday

MT Newswires Live
·
Sep 14

Evercore ISI Remains a Buy on UnitedHealth (UNH)

TIPRANKS
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

J&J - Jnj Reports Rybrevant Plus Chemotherapy Extends Pfs2 by 10.8 Months in Nsclc

THOMSON REUTERS
·
Sep 14

Johnson & Johnson’s Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Delivers Longest Reported Median Overall Survival in Egfr Exon 20 Insertion Mutation-Positive Lung Cancer

THOMSON REUTERS
·
Sep 14

J&J - Jnj Reports no New Safety Signals for Rybrevant Plus Chemotherapy in Nsclc Study

THOMSON REUTERS
·
Sep 14

Scholar Rock Wins FDA Approval for SMA Therapy

TIPRANKS
·
Sep 14

Potential Buyer Emerges for Johnson & Johnson's Orthopedics Unit

Deep News
·
Sep 14

Scholar Rock price target raised to $84 from $76 at BMO Capital

TIPRANKS
·
Sep 14

Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell

MT Newswires Live
·
Sep 14

Perspective Therapeutics Partners with Merck to Test [212Pb]PSV359 with Keytruda in FAP-Α-Positive Solid Tumors

Reuters
·
Sep 14

Perspective Therapeutics, - Co Sponsors Study; Merck Provides Pembrolizumab at no Cost

THOMSON REUTERS
·
Sep 14

Johnson & Johnson reports PAPILLON study meets primary endpoint

TIPRANKS
·
Sep 14